Download - SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

Transcript

Page 1: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 2: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 3: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 4: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 5: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 6: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 7: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 8: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 9: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 10: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 11: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 12: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Top Related

Placebo #7

Placebo Effect

Pertuzumab in combination with trastuzumab and docetaxel

Pertuzumab in combination with trastuzumab and docetaxel

Willkommen bei oncoletter - Oncoletter, Webportal für ...€¦ · ACE-536 has corrected anemia in various murine preclinical models of ineffective erythropoiesis such as MDS and

Willkommen bei oncoletter - Oncoletter, Webportal für ...€¦ · ACE-536 has corrected anemia in various murine preclinical models of ineffective erythropoiesis such as MDS and

125409Orig1s000 · evaluating the safety and efficacy of pertuzumab + trastuzumab + docetaxel vs. placebo + trastuzumab + docetaxel in previously untreated HER2-positive metastatic

125409Orig1s000 · evaluating the safety and efficacy of pertuzumab + trastuzumab + docetaxel vs. placebo + trastuzumab + docetaxel in previously untreated HER2-positive metastatic

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive

Australian public assessment for Pertuzumab€¦ · Web viewresults of a tissue cross-reactivity study suggest tissue binding in monkeys and humans. Tissue cross-reactivity to pertuzumab

Australian public assessment for Pertuzumab€¦ · Web viewresults of a tissue cross-reactivity study suggest tissue binding in monkeys and humans. Tissue cross-reactivity to pertuzumab

TRATAMIENTO NEOADYUVANTE CON PERTUZUMAB EN … · (pertuzumab y trastuzumab) en el tratamiento neadyuvante del cáncer de mama HER2+ TRATAMIENTO NEOADYUVANTE CON PERTUZUMAB EN CANCER

TRATAMIENTO NEOADYUVANTE CON PERTUZUMAB EN … · (pertuzumab y trastuzumab) en el tratamiento neadyuvante del cáncer de mama HER2+ TRATAMIENTO NEOADYUVANTE CON PERTUZUMAB EN CANCER